Biotech firms flock to Hong Kong IPO, ‘A+H’ listing favored

The surge in biotech listings underscores Hong Kong's deepening role as a capital gateway for life sciences, particularly for A-share companies seeking dual-market access. The high filing volume signals sustained pipeline demand, though repeated filings hint at selectivity or timing hurdles. For market watchers, the key dynamic is whether HKEX can maintain this momentum amid global liquidity shifts and whether the dual-listing trend accelerates cross-border capital integration. The breadth across oncology and medical devices suggests sector diversification, but concentration risk remains if capital continues favoring later-stage or dual-listed names over early-stage pure plays.